Cargando…
PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320365/ https://www.ncbi.nlm.nih.gov/pubmed/30675511 http://dx.doi.org/10.1038/s41523-018-0098-y |
| _version_ | 1783385210020167680 |
|---|---|
| author | Pondé, Noam Gelber, Richard D. Piccart, Martine |
| author_facet | Pondé, Noam Gelber, Richard D. Piccart, Martine |
| author_sort | Pondé, Noam |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6320365 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63203652019-01-23 PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? Pondé, Noam Gelber, Richard D. Piccart, Martine NPJ Breast Cancer Comment Nature Publishing Group UK 2019-01-04 /pmc/articles/PMC6320365/ /pubmed/30675511 http://dx.doi.org/10.1038/s41523-018-0098-y Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Comment Pondé, Noam Gelber, Richard D. Piccart, Martine PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? |
| title | PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? |
| title_full | PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? |
| title_fullStr | PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? |
| title_full_unstemmed | PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? |
| title_short | PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? |
| title_sort | persephone: are we ready to de-escalate adjuvant trastuzumab for her2-positive breast cancer? |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320365/ https://www.ncbi.nlm.nih.gov/pubmed/30675511 http://dx.doi.org/10.1038/s41523-018-0098-y |
| work_keys_str_mv | AT pondenoam persephonearewereadytodeescalateadjuvanttrastuzumabforher2positivebreastcancer AT gelberrichardd persephonearewereadytodeescalateadjuvanttrastuzumabforher2positivebreastcancer AT piccartmartine persephonearewereadytodeescalateadjuvanttrastuzumabforher2positivebreastcancer |